Trials / Terminated
TerminatedNCT00182533
Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
Sertraline in the Treatment of Generalized Social Phobia With Comorbidity
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- Sponsor
- Hamilton Health Sciences Corporation · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders.
Conditions
- Phobia, Social
- Panic Disorder
- Agoraphobia
- Obsessive-Compulsive Disorder
- Anxiety Disorders
- Major Depressive Disorder
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sertraline | 25 - 200 mg/day x 16 weeks |
| DRUG | Placebo | 25 - 200 mg/day x 16 weeks |
Timeline
- Start date
- 2002-07-01
- Primary completion
- 2018-01-01
- Completion
- 2018-01-01
- First posted
- 2005-09-16
- Last updated
- 2018-03-22
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00182533. Inclusion in this directory is not an endorsement.